Case Western, Picture Health partner to develop AI tools for lung cancer

More than half of cancer centers see AI as answer to operational challenges, report shows

LeanTaaS Inc. has conducted a national survey of nearly 200 nursing and operational leaders from community hospitals, academic medical centers, and private oncology practices.

July 03, 2025

Vol.51 No.26

Clinical Trials & Tribulations

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers.

June 27, 2025

Vol.51 No.25

By Ghulam Rasool, Brian D. Gonzalez and Katherine Chung-Bridges

Clinical Roundup

City of Hope launches AI tool to reduce burden of cancer care

City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials, and empower breakthrough research.

June 27, 2025

Vol.51 No.25

In Brief

City of Hope awarded $23.7M from ARPA-H for biomarker mapping

City of Hope has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the U.S. Department of Health and Human Services. The grant will help City of Hope create a biomap of tumor changes that cause immunotherapy resistance in advanced or metastatic non-small cell lung cancer.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC

FDA has approved Ibtrozi (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

June 13, 2025

Vol.51 No.23